<SEC-DOCUMENT>0001144204-14-037220.txt : 20140624
<SEC-HEADER>0001144204-14-037220.hdr.sgml : 20140624
<ACCEPTANCE-DATETIME>20140612132347
ACCESSION NUMBER:		0001144204-14-037220
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		5
CONFORMED PERIOD OF REPORT:	20140609
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20140612
DATE AS OF CHANGE:		20140612

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BIOANALYTICAL SYSTEMS INC
		CENTRAL INDEX KEY:			0000720154
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]
		IRS NUMBER:				351345024
		STATE OF INCORPORATION:			IN
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-23357
		FILM NUMBER:		14906668

	BUSINESS ADDRESS:	
		STREET 1:		2701 KENT AVE
		CITY:			WEST LAFAYETT
		STATE:			IN
		ZIP:			47906-1382
		BUSINESS PHONE:		3174634527

	MAIL ADDRESS:	
		STREET 1:		2701 KENT AVENUE
		CITY:			WEST LAFAYETTE
		STATE:			IN
		ZIP:			47906-1382
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>v381314_8k.htm
<DESCRIPTION>8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">UNITED STATES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">SECURITIES AND EXCHANGE COMMISSION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Washington, D.C. 20549</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">FORM 8-K</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">CURRENT REPORT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Date of Report (Date of earliest event reported):
June 9, 2014</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; border-bottom: black 1pt solid; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">BIOANALYTICAL SYSTEMS, INC.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">(Exact name of registrant as specified in its charter)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 33%; border-bottom: black 1pt solid; padding: 0; text-align: center"><FONT STYLE="font-size: 10pt">Indiana</FONT></TD>
    <TD STYLE="width: 1%; padding: 0; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 32%; border-bottom: black 1pt solid; padding: 0; text-align: center"><FONT STYLE="font-size: 10pt">0-23357 </FONT></TD>
    <TD STYLE="width: 1%; padding: 0; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 33%; border-bottom: black 1pt solid; padding: 0; text-align: center"><FONT STYLE="font-size: 10pt">35-1345024</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; padding: 0"><FONT STYLE="font-size: 10pt">(State or other <BR>
jurisdiction of <BR>
incorporation or<BR>
 organization)</FONT></TD>
    <TD STYLE="padding: 0; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center; padding: 0"><FONT STYLE="font-size: 10pt">(Commission File Number)</FONT></TD>
    <TD STYLE="padding: 0; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center; padding: 0"><FONT STYLE="font-size: 10pt">(I.R.S. Employer Identification<BR>
 No.)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 65%; border-bottom: black 1pt solid; padding: 0; text-align: center">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">2701 KENT AVENUE</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">WEST LAFAYETTE, INDIANA</P></TD>
    <TD STYLE="width: 2%; padding: 0; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 33%; border-bottom: black 1pt solid; padding: 0; text-align: center">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">47906-1382</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; padding: 0"><FONT STYLE="font-size: 10pt">(Address of principal executive offices)</FONT></TD>
    <TD STYLE="padding: 0; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center; padding: 0"><FONT STYLE="font-size: 10pt">(Zip Code)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Registrant's telephone number, including
area code: (765) 463-4527</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify">Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify">Soliciting material pursuant to Rule 14a-12 under the
Exchange Act(17CFR240.14a-12)</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify">Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act(17CFR240.14d-2(b))</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify">Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act(17CFR240.13e-4(c))</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 1in; text-align: left"><B>Item 5.02</B></TD><TD STYLE="text-align: justify"><B>Departure of Directors or Certain Officers; Election
of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On June 5, 2014, the Board of Directors
of Bioanalytical Systems, Inc. (the &quot;Company&quot;) approved certain changes to the Company's senior management. Jeffrey Potrzebowski
joined the Company as Chief Financial Officer (CFO) and Vice President of Finance, effective June 9, 2014. Mr. Potrzebowski succeeds
Jacqueline M. Lemke, who relinquished her duties as CFO and Vice President of Finance on June 9, 2014, but remains the Company&rsquo;s
President, CEO and a member of the Board of Directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Prior to joining BASi,
Mr. Potrzebowski, 61, served in various positions of increasing responsibility at Oerlikon Drive Systems from 2006 &ndash; 2013,
most recently as CFO of this $800 million manufacturer of gear and drive solutions, where he was responsible for the management
and control of the financial performance of the Operating segment reporting to the Segment CEO. Prior, from 2005-2006, Mr. Potrzebowski
served as Senior Vice President and CFO of Remy International, a producer of electrical automotive parts with sales in excess of
$1.2 billion. Previously, he was Senior Vice President and CFO of Great Lakes Chemical, a $1.6 billion specialty chemical company,
which he joined in 1993. Mr. Potrzebowski is a Certified Public Accountant (CPA) and began his career at Pricewaterhouse Coopers,
LLC. He earned his bachelor&rsquo;s degree in accounting from Toledo University.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Effective June 9, 2014, Mr. Potrzebowski&rsquo;s
base salary is $16,666.67 per month with a targeted Annual Incentive Bonus payout of 30% of base salary. In addition to reimbursement
of business expenses in accordance with the Company&rsquo;s standard reimbursement policies, Mr. Potrzebowski will be entitled
to a $500 monthly commuting allowance. Mr. Potrzebowski is also eligible to participate in all employee benefit plans which are
generally made available to employees of the Company, subject to the eligibility, qualification, waiting period and other terms
and conditions of such plans as they shall be in effect from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">In
connection with his employment, BASi granted Mr. Potrzebowski an option to purchase 10,000 shares of the Company's common stock
pursuant to the Company's Employee Stock Option Plan and an Option Agreement dated June 9, 2014.&nbsp; The grant is effective on
June 9, 2014 at a price of $2.66 (the closing price of the Company's common shares on June 6, 2014). The option vests in three
equal annual installments beginning June 9, 2015, with the second and third installments becoming exercisable on the two succeeding
anniversary</FONT> <FONT STYLE="font-size: 10pt">dates, subject to Mr. Potrzebowski&rsquo;s continued employment with BASi. This
option grant expires on the tenth anniversary of the effective date of the grant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On June 12, 2014, the Company issued a press
release announcing the hiring of Mr. Potrzebowski. The full text of the press release is furnished as Exhibit 99.1 to this Form
8-K and is incorporated herein by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 1in; text-align: left"><B>Item 9.01.</B></TD><TD STYLE="text-align: justify"><B>Financial Statements and Exhibits.</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(d)&nbsp;&nbsp;Exhibits:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 40.5pt">99.1</TD><TD>Bioanalytical Systems, Inc. press release, issued June 12, 2014.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt; text-transform: uppercase">Bioanalytical Systems, Inc. </FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0; width: 50%">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; width: 4%">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; width: 36%">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; width: 10%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">Date: June 12, 2014</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt"><U STYLE="text-decoration: none">/s/ Jacqueline M. Lemke</U></FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">Jacqueline M. Lemke</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">President and CEO</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.5in; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.5in; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.5in; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.8in; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Exhibit Index</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 15%; padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt"><U>Exhibit No.</U></FONT>&nbsp;&nbsp;</TD>
    <TD STYLE="width: 85%; padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt"><U>Description</U></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">99.1&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">Bioanalytical Systems, Inc. press release, issued June 12, 2014.</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.8in; text-indent: 0.5in">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>v381314_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: left; font-size: 10pt"><IMG SRC="image_03.jpg" ALT=""></TD>
    <TD STYLE="width: 50%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right; font-size: 10pt"><IMG SRC="image_04.jpg" ALT="">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr>
    <td style="width: 53%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">FOR MORE INFORMATION:</font></td>
    <td style="width: 47%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif"><b>Company Contact:&nbsp;</b></font></td></tr>
<tr>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">Jacqueline Lemke&nbsp;</font></td></tr>
<tr>
    <td colspan="2" style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">President &amp; CEO&nbsp;</font></td></tr>
<tr>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">Phone:&nbsp;&nbsp;765.497.5829&nbsp;</font></td></tr>
<tr>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><U>jlemke@BASinc.com<FONT STYLE="color: blue">&nbsp;</FONT></U></FONT></td></tr>
<tr>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td></tr>
<tr>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif"><b>Agency Contact:</b>&nbsp;</font></td></tr>
<tr>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">Neil Berkman&nbsp;</font></td></tr>
<tr>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">Berkman Associates&nbsp;</font></td></tr>
<tr>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">Phone:&nbsp;&nbsp;310.477.3118&nbsp;</font></td></tr>
<tr>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><U>info@berkmanassociates.com<FONT STYLE="color: blue">&nbsp;</FONT></U></FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.2in 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.2in 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.2in 0pt 0; text-align: center"><B>BASi Names Jeffrey Potrzebowski
CFO and</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.2in 0pt 0; text-align: center"><B>James Bourdage VP Bioanalytical
Operations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.2in 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.2in 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.2in 0pt 0; text-align: justify; text-indent: 13.5pt"><B>WEST
LAFAYETTE, IN </B>&ndash; June 12, 2014 -- <B>Bioanalytical Systems, Inc. (NASDAQ:BASI) </B>today announced the appointment of
Jeffrey Potrzebowski as Chief Financial Officer and James S. Bourdage, Ph.D., as Vice President Bioanalytical Operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.2in 0pt 0; text-align: justify; text-indent: 13.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.2in 0pt 0; text-align: justify; text-indent: 13.5pt">BASi President
&amp; CEO Jacqueline Lemke said, &quot;These appointments represent significant steps forward in our continuing program to build
a management team with the depth, experience and dedication to take BASi to the next level and achieve our goals for growth and
profitability. Each of these senior executives brings an impressive record of accomplishment to his new role at BASi: Jeff Potrzebowski
in financial management, reporting, planning and related public company CFO functions; and Jim Bourdage in the leadership and management
of large global laboratory operations in the pharmaceutical and biotech industries. We welcome Jeff and Jim to BASi, and look forward
to their contributions to our continued success.&quot;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.2in 0pt 0; text-align: justify; text-indent: 13.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.2in 0pt 0; text-align: justify"><B>Jeffrey Potrzebowski, CPA</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.2in 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.2in 0pt 0; text-align: justify; text-indent: 13.5pt">Jeffrey
Potrzebowski joins BASi after serving since 2006 in various positions of increasing responsibility with Oerlikon Drive Systems,
Lafayette, Indiana, most recently as Chief Financial Officer of this $800 million manufacturer of gear and drive solutions, where
he was responsible for the management and control of financial performance of the Operating Segment reporting to the Segment CEO.
Earlier, he was Senior Vice President and Chief Financial Officer of Remy International, Anderson, Indiana, a producer of electrical
automotive parts with sales in excess of $1.2 billion. Previously, Mr. Potrzebowski was Senior Vice President and Chief Financial
Officer of Great Lakes Chemical, Indianapolis, a $1.6 billion specialty chemical company, which he joined in 1993.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.2in 0pt 0; text-align: justify; text-indent: 13.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.2in 0pt 0; text-align: justify; text-indent: 13.5pt">Mr. Potrzebowski
began his career with Price Waterhouse in Toledo. He received a BA in Accounting from Toledo University in 1975 and a CPA in 1976.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.2in 0pt 0; text-align: justify; text-indent: 13.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.2in 0pt 0; text-align: justify"><B>James S. Bourdage, Ph.D.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.2in 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.2in 0pt 0; text-align: justify"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.2in 0pt 0; text-align: justify; text-indent: 13.5pt">James S.
Bourdage was Executive Director Biopharmaceutical CMC Solutions at Covance Inc., Greenfield, Indiana, since 2011, where he was
responsible for the US Biotechnology CMC operation of this $2.4 billion drug development services organization. Earlier, he was
Senior Director, Bioanalytical Sciences, at Pharmathene, Inc., Annapolis, Maryland, a biodefense company with more than $300 million
in government contracts. From 2003 to 2009, Dr. Bourdage was Global Research Advisor and Team Leader, Laboratory for Experimental
Medicine at Eli Lilly Co., Indianapolis, where his responsibilities included oversight of biotherapeutic immunogenicity and biomarker
assay development to support global clinical trials. Previously, he was Senior Research Scientist, Drug Absorption and Transport
at Pharmacia (Upjohn), Kalamazoo, Michigan, where he received the Upjohn Corporate Special Recognition Award in 1992 and the Quality
Control Achievement Award in 1993.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.2in 0pt 0; text-align: justify; text-indent: 13.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.2in 0pt 0; text-align: justify; text-indent: 13.5pt">Dr. Bourdage
received a Ph.D. in Immunochemistry from the University of Illinois in 1979. He is a member of the American Society of Clinical
Pathologists and the American Association of Pharmaceutical Scientists, and is the author of numerous scientific papers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.2in 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.2in 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.2in 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.2in 0pt 0; text-align: justify"><B>About Bioanalytical Systems,
Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.2in 0pt 0; text-align: justify; text-indent: 13.5pt">BASi is
a pharmaceutical development company providing contract research services and monitoring instruments to the world's leading drug
development companies and medical research organizations. The company focuses on developing innovative services and products that
increase efficiency and reduce the cost of taking a new drug to market. Visit www.BASinc.com for more about BASi.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.2in 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.2in 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.2in 0pt 0; text-align: justify; text-indent: 13.5pt"><I>This release contains forward-looking
statements that are subject to risks and uncertainties including, but not limited to, risks and uncertainties related to changes
in the market and demand for our products and services, the development, marketing and sales of products and services, changes
in technology, industry standards and regulatory standards, and various market and operating risks detailed in the company's filings
with the Securities and Exchange Commission.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.2in 0pt 0; text-align: justify; text-indent: 13.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.2in 0pt 0; text-align: justify; text-indent: 13.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.2in 0pt 0; text-align: right; text-indent: 13.5pt"><IMG SRC="image_001.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.2in 0pt 0; text-align: justify; text-indent: 13.5pt"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.2in 0pt 0; text-align: justify; text-indent: 13.5pt">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X``02D9)1@`!`0```0`!``#_VP!#``@&!@<&!0@'!P<)"0@*#!0-#`L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+#`Q-#0T'R<Y/3@R/"XS-#+_
MVP!#`0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P``1"``V`CH#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#W^BBB@`HH
MHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB
M@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`
M"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`A
MN_\`CRG_`.N;?RJ+3/\`D%6?_7!/_014MW_QY3_]<V_E46F?\@JS_P"N"?\`
MH(H`MT444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%
M%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`444
M4`%%%%`!115"[OBADCA,:F,9EFD/R1#KSR,G'./3J1QE-V!*^Q?HKSS4O'&E
M0RE8H[G4W!Y>23RXS]%''_COXUF?\)W:$Y/AJQ_3_P")KCGF.&B[.1W0RW$S
M5U$]6HKRG_A.K/\`Z%JQ_P#'?_B:/^$ZL_\`H6K'_P`=_P#B:C^T\-_-^!7]
MEXK^7\4>K45Y3_PG5G_T+5C_`..__$T?\)U9_P#0M6/_`([_`/$T?VGAOYOP
M#^R\5_+^*/5J*\I_X3JS_P"A:L?_`!W_`.)H_P"$ZL_^A:L?_'?_`(FC^T\-
M_-^`?V7BOY?Q1ZM17E/_``G5G_T+5C_X[_\`$T?\)U9_]"U8_P#CO_Q-']IX
M;^;\`_LO%?R_BCU:BO*?^$ZL_P#H6K'_`,=_^)H_X3JS_P"A:L?_`!W_`.)H
M_M/#?S?@']EXK^7\4>K45Y3_`,)U9_\`0M6/_CO_`,31_P`)U9_]"U8_^.__
M`!-']IX;^;\!_P!E8K^7\4>K45Y3_P`)U9_]"U8_^.__`!-'_"=6?_0M6/\`
MX[_\31_:>&_F_`/[*Q7\OXH]6HKRG_A.K/\`Z%JQ_P#'?_B:/^$ZL_\`H6K'
M_P`=_P#B:/[3PW\WX!_96*_E_%'JU%>4_P#"=6?_`$+5C_X[_P#$T?\`"=6?
M_0M6/_CO_P`31_:>&_F_`7]EXK^7\4>K45Y3_P`)U9_]"U8_^.__`!-'_"=6
M?_0M6/\`X[_\31_:>&_F_`/[+Q7\OXH]/N_^/*?_`*YM_*HM,_Y!5G_UP3_T
M$5YG)XWM)(F0>'+%=P(!&.,_\!KTS2S_`,2BRX_Y8)_Z"*Z*&)IU[^S=['/7
MPM6A;VBM<N4445T'.%%%%`!1110`52OKXV30_P"CR2K(X3<K+\I/L3D\9/'8
M&KM036L<\T,DF28BQ5<\9(QG\B?SH`RX/$EK<-;A$P)V(4M(@_N>_7YQQUJQ
M>ZU;V5RT$BL66,.6&`H)95`))X.77\#3(M!MHD5!-<%`5W*7&'5=NT$8[;1S
MUZ\\FG2Z#9RR+*V_SU`'G`C<S`H0QXY(*+0`ZTUB.ZN8H5A=3+'YBL64@CCT
M)XYQGID&H#XAM?/:)4;B<P[F95!("DD$GI\PJ:+1H86C9)[D>7G:-XX)QDCC
MOCD=.3QFF_V!9*)5A\R&.4@R1QMA6&`-N/3Y1[]<&@!LNMF/S`+"X9HV567<
M@.6.%ZGJ?3Z5KUG6^CPV^W]]-(%F,X$A'WL'K@#/WL_@*T:`(+JX6TM)KAU9
MEB0N0O4@5EGQ):A/,\J5D`.67:1N&_`'/.=AP>G(]:U;JW2[MI(),['&"0<$
M5G'P]:-NW/.V[<7RP^9CO^8\=?WC=./;B@!UQKD-K8"ZEBD`\UXF3*Y5EW9Y
MSC^$X]<BFW&OVT$TL>UCY3JA8L%7)#'J3VV$'WXITFA02P^6UQ<<LS$[EZMO
M#'ICD.0>.PQBE;0;,-*T/FVYE`5_*;&1\V<COG<?T/44`2W>J16EQ;0&.222
MXW;5C`.-JEOUVD"JS>(;:)4,L4J,7D5QP=FP$L20>G&/_P!1J6;0[.9HG;S!
M+%G9(K891M8`9]!O.*C_`.$<L&@BBE5I1&-JLV`=N&&W@#CYC0!<L+Y-0MO.
M1=HW%<;U;D>ZDBK=5K.S2RB9$=W+MO9W(RQP!V`'0#\JLT`%9<>NVDD,4N)0
M)8VE0;<DJ!GMWQG`]C6I62?#]D4B4>:OE1+$K*^"%`*]NY#'F@":?4UBTS[?
M#"\\7)^4@97GYADC(.!CUR*J/XEME,@,9#1OL8&1!@Y(.>>,$&K_`/9\'V..
MTR_DQNK*N>@5MP7Z#`&/057;1(#-)*D]Q&[EB-C`;=QRP''().><^V*`)+S5
MH++[/Y@9C,"PV8.`%R2:@BUP2R1*MG-\\PA)W)\K8W=CS\ISQ4K:'9-Y)96+
M0X\ML\J`"`H/H,FEM-&MK,QF(ON3<<\#)8`9P`!G"@4`+=ZK':+>EXIF%I")
MGV@?,IW=/^^33'UA%NY+9+>5W7(!&,-C;NY)XQO'7T-33:9#/%<1R/(WVBW%
MM(Q;DJ-W/U^<U7NM"MKN25WDF7S.H4C`R5)ZCOL7.<_J:`+UI<+>6<-RBLJ2
MHKJ&Z@$9YJ>F1IY<2IO9]H`W-C)^N*?0!2NM3L[.817$PC<XP"#SG./Y&J__
M``D.EA"YN2`%+<QMG`)!XQ_LG\JDU+1K752AN-X**5&QL=<<_48XJ)O#]B]X
MURRN68M\N>!N7:1CZ<_4FL).M?W;6-HJCR^]>XZ;7;-+6YFB?S3;_?7E<?,5
MZD>JG\JKIXC@D-MM@D83"3[I#8*9].N[:V#WQ3T\.6D4,D4<LZB155SN!)VC
M`ZC\?J31_P`(W8G<S&5I6(;S=V&!W%C@CIDLW3UJ?W_D4O8>8V'Q';MY9EC9
M%D4LK(?,!P5'&W/][]#5R+6+"97:.?*I'YI8J0NW`.<D8/!'TS5>/P_:I.)V
MDF>8MN9V(^8_+U``'\"TD7AZVBMS;K-<?9V3RS%OPI&W:>W?`_ICFG'VRWL*
M7L7M<E;7M.09>=EPI8[HF!`&[.>.#\K<=>#4]IJ=I?2.EO(S-']X,C+CDCN!
MW4C\*IR^'[><DS3W$C,I#%F'S9##/3L'8#''MP*MVFFP6<\DT1;<X(.3QR[/
M_-S51=6^MK$R]G;2]R[1116QD%%%%`!1110!6O9VM[5I$&9"0B`]"S'`S[9(
MKS#QSK+?:!HEM(WV>WYG;/,LAY)/KUS]?H*]+OCF>Q4]#<'CZ1N1^H%>'ZNY
MDUJ^=CDM<2$Y_P!XUY6;590I**ZGKY/1C.LY2Z%*M6/1DDL[6X^U@^?((MB1
MDD,>@'//;/ID5E5I)K4Z"RVPP!K/_5-M.>YYYQU.?K7SU/DUYSZ.K[33D+9\
M-DP+*E]"5:7RP2I`VEW0-GW*'CW%1V/A^2^O;ZW2=5^QGYW*\;0V"?P&35=-
M9NDL(;-1'Y<3JP;;\QPS,`>>F6/YTMKKEY9W=Q<PE%DN'#OP?[^['7ID8^E;
M<U"ZTTZG/RXGE>NO0<GA_495B>*(&.4%D9I%7Y?4\\<<TAT2X2_LK.1D62YZ
MX(/E_.5.<'MM)J3_`(2.]$<:*D`"(8Q\I^Z>,=>PJ)M;NVO8KL"-9XU=5901
MC>6)/7J"YQ2_<>97^TOL2R^'-16Y>**(2H'*+(&4!N0,XSQ]X'\::?#NJ#/^
MCJ<.(\>:O))4#'/3+KSTY%2?\)-J.$RR$K(LA8@DL50)R<]P!GW%(/$E\&W*
ML(PX<`*>"&1O7UC7]:=L-YDWQ=MD5CHU^+.2Z,($2*KD[QG!`((&>>&4^V:H
M5J2Z]=36DML4A$4BJH4*?D`55XR?15ZYK+K&I[._N'12]HU^\-RP\-3:A:17
M$4P"/L!ROW2TA3U[8W?2H/\`A'M1(5EB3RW0R*[2*HV_+UR>#\Z]?[PI+'Q!
M?:?:+;0%/+5F8;ER>1C].H]ZDB\27L3P.(X&:%-BEE).,*/7T0#`P#SD<FMU
M]7<5>]SG:Q2D[6:(FT=TGEB:9/W=H+K*\@@J&QU]^M+::%<W4*7!,:6[*[;]
MZG&U2V",\$@=Z9'K$\=QYQBA<FW%LRLIPR``<\]<`5*WB&[:T6U$<"1*K(`J
MG@,K+CKZ.:E>PO=[%/ZS:RM<8V@:DH#>0K*5W;EE4C'S=\_[+?E5J#PK?R2^
M5,8X&R@&YU.=S%?7L1R*'\3W4Z7'G(FZ6W:!=F0%#-DGDGW`],TQO$]^UQYQ
M6#?\I)V'DJV[/7_(Z8J[89/J1?%M6LBC=:9=V5M#<3QA8YN4(<-V![=."#^-
M:%AX;EU"R2XCN%!:,OL*]@^T\Y],G\*JSZS+=01PSP0ND<91,`Y'RA0><]`!
MBG6FOWME;Q0P^6%BQM)!S]\/_,?E6<?8*;OL7+ZPX*WQ#8='DFEU!1(H2S5R
MSD?>*YX'N0"?PJ[;>&3=JI@NP=T8=0T9!Y+!<^@.T\_2J$&M7MNUV8W4+=;O
M,7;Q\V<G]:DMM>O+6Y>>+RP[0K".#\JJN!CGV^E.+H=4$UB->5E]/",SD8NE
M(V9?;&25;Y.,=_OC]>*YSV/6MM?%-^K(=D!V`<%#@L"I#'GKE%]N.E8I.22>
M]36=)V]F5059-^U^0E>_:7_R"++_`*X)_P"@BO%O#VC3:YJT5K&#Y>0TKC^!
M>YKW)5V*%4`*!@#TKVLGIR5.4GU/#SJK%U(Q70H_\3G_`*</_'Z/^)S_`-.'
M_C]%%>R>*'_$Y_Z</_'Z/^)S_P!.'_C]%%`!_P`3G_IP_P#'Z/\`B<_].'_C
M]%%`!_Q.?^G#_P`?H_XG/_3A_P"/T44`'_$Y_P"G#_Q^C_B<_P#3A_X_110`
M?\3G_IP_\?H_XG/_`$X?^/T44`'_`!.?^G#_`,?H_P")S_TX?^/T44`'_$Y_
MZ</_`!^C_B<_].'_`(_110`?\3G_`*</_'Z/^)S_`-.'_C]%%`!_Q.?^G#_Q
M^C_B<_\`3A_X_110`?\`$Y_Z</\`Q^C_`(G/_3A_X_110`?\3G_IP_\`'Z/^
M)S_TX?\`C]%%`!_Q.?\`IP_\?H_XG/\`TX?^/T44`'_$Y_Z</_'Z/^)S_P!.
M'_C]%%`!_P`3G_IP_P#'Z/\`B<_].'_C]%%`!_Q.?^G#_P`?H_XG/_3A_P"/
MT44`'_$Y_P"G#_Q^C_B<_P#3A_X_110`?\3G_IP_\?H_XG/_`$X?^/T44`'_
M`!.?^G#_`,?H_P")S_TX?^/T44`'_$Y_Z</_`!^C_B<_].'_`(_110`?\3G_
M`*</_'Z/^)S_`-.'_C]%%`!_Q.?^G#_Q^C_B<_\`3A_X_110`?\`$Y_Z</\`
MQ^C_`(G/_3A_X_110!#-!J\TD#EK$>2Y<8W\_*R_^S5QMQ\-KVYNI9SJ%N#(
MY<C8>,G-%%8U:%.LOWBN;4<14H-NF[7(_P#A5]Y_T$8/^^#1_P`*OO/^@C!_
MWP:**P_L_#?RF_\`:6*_G#_A5]Y_T$8/^^#1_P`*OO/^@C!_WP:**/[/PW\H
M?VEBOYP_X5?>?]!&#_O@T?\`"K[S_H(P?]\&BBC^S\-_*']I8K^</^%7WG_0
M1@_[X-'_``J^\_Z",'_?!HHH_L_#?RA_:6*_G#_A5]Y_T$8/^^#1_P`*OO/^
M@C!_WP:**/[/PW\H?VEBOYP_X5?>?]!&#_O@T?\`"K[S_H(P?]\&BBC^S\-_
M*']I8K^</^%7WG_01@_[X-'_``J^\_Z",'_?!HHH_L_#?RA_:6*_G#_A5]Y_
MT$8/^^#1_P`*OO/^@C!_WP:**/[/PW\H?VEBOYP_X5?>?]!&#_O@T?\`"K[S
M_H(P?]\&BBC^S\-_*']I8K^</^%7WG_01@_[X-'_``J^\_Z",'_?!HHH_L_#
M?RA_:6*_G#_A5]Y_T$8/^^#4UM\+V\P&ZU(;`>1%'R1]2>***:P&'3^$'F.)
E:LYG;:3H]EHMI]GLHMBGEF/+.?4FM#BBBNM12T1Q\SEJ]S__V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>image_03.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_03.jpg
M_]C_X``02D9)1@`!`0```0`!``#_VP!#``$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0'_
MVP!#`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0'_P``1"`!(`*D#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#^_BBBB@`H
MHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@#+CBC-Q#,%8,/-
M()VA#O1-S88;LA2%#@KD'"$QR.*U*KEE`Y``V\X`QE0,`$]L;1CTI<GU/YFM
M)*<[-VT7+K*^BNUJH]+V_P"!HN=2ITFVHM.JW5F]>:<FW34I)R:35.E2INUD
MW2;:O=N>BBBLSH/B']N+]L'1/V-_A';^.)]`7Q9XL\1ZU#X9\%^&#>MI]E>:
MF;6>\N=2U>]$%S<VVD:+86[W-T;:UEN+JYDL-/4VJW9N[3\@/@__`,%R/'T?
MBF.'XZ_"OP9>^#;JY2&XU+X8C6M&\0:':M@F[73/$NO>(-.\3"W(`-L-6\/%
M5)87)=4M+K]&?^"JW[-NO_'[]FF\N?!=K=:KXT^$VLI\0-'T:T@2XOM=T>VT
MV[T[Q/H]E;H?M%Q??V1.^J6%O:`WE]?:3!86FV[N(ZP_^"=W@?X2?!/]AWPI
M\7?"GA*Y\8:]XJ\'W_C3Q_J7A70[/7O'OB:_MKN^BU3PGID'VBWGOD\,-93Z
M)I_ANUN5MWO-*O+I+*36M0O&N?Y:XL?C)GGCC2X9X>XS7!7"V!X1PO$."Q#R
MO"YMA,XDL7AL%F>%Q>%Q:PD<9BECL3'#8J*QN%6$P?U7$_[+B,5AY5_ZHX.E
MX&</>`-7BSBC@E\<<:8_C+&\,8S"?V[C<EQ>21E@<3CLJQF#Q>">*CE>$_LC
M"RQ6$Q<\OQT\=CUB\*XQP>$Q7L/OGP]\8?"OCWX2_P#"X/A7)+\5O#EYX>O-
M=\.67A*6T;5?%$VGP7`;0;"'6+C2;:Q\0-?V[:4=.UN[L;FSU/-GJ*V=TK(-
MKX7_`!,\'?&'P5I?COP)J+:EH6J>?$T4\4ECJ^D:I8S-:ZKX?\1:7<JMUHWB
M+0KZ*?3-9TJ[C^TV-Y!)&3M(<^*?`WX;?">W\17GQR_9Z\7P6?PS^+.C-J?B
M'P1X5&FO\.=>\7B:R-OX]T_31;I<^$/%UO90WVA>+]-L5TU]6NEL?^$@L+;7
M-`8W/Y9_#[]L7PQ\/O\`@J7\2O`W@+6+35/@G\=_&/A;P9K2:9<Q7/A\?&"?
M0-#T(>,?#H@;R/M&J>.()_"VN7-LYM-9%]<ZV7OOLND,?Z-RB6;RP-*.>T<)
M0S3#_P"S8MX-OZGBYQLEC,(I?[5A,+BV^983&7Q6$=\(\3BN6.+Q?\T9O3RB
M&-K?V#B<96RRM_M6#>.4%C<+&2;>#QC@_JF+Q>$^&6,P26$Q=OK<<+A>:>%P
MGZ*_M\67B_1?V>?B5\5/A[\3O'_PW\8?#GPA>Z_I4_A764@TG4/[*F:[N+#5
M]%OK6YMKC[7;RS0->0?9+ZW`@9;DI;"WG_*/_@F;\4/V@/VO/&?Q0\*_%+]H
M_P"-$%CX3\+:-KVE2>&=>T;2[K[7?:O<V4T4TE_X=U$7,!B"XS;IQ"<$MM-?
MK[^WUO;]C3]H[!!0?"KQ(3R"!(+4`J"I()"A\'N#UK\*/^",\GQ!A\5_M%2_
M#"T\*ZAXW7X=>$O[%M/&MYJNG^'9#_PER&\_M&^T/3M4U&W/V`3?8OLUK>*;
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MA_P4+\+_`!^?XL^`?B3^W?X:-W\$H99O"_A5?V9]>L6TOP^]ZZZI?:*UYXZ\
M/KJ\GB?6;6R2>^NM:T[2;35#IJ#2&L[>U:RM?TTT_P#:I^`_@_\`8+36OV.8
M6@>.6P^"OPA\`S1>7XNTOXP^.;Q;#1]+UK3]1N[L7^M6MYJ][XUU*Y>_O;7Q
M#:66H:A9:I>I=K*_+X?<5XO(O%3Q7EF/$F;Y1P5E&68O&99X><68K-L9Q)*.
M$PF6XR6=9+@LU>/Q7]E8NV9K!8;!YA5EBWF6#PBP=K?4]?$?A/`<0>#O@Y_9
MG#>3YSQ[F^:X/)LW\2^$<)D^!X-MC<7FF$P61\3YQE<,OP?]N8*#RIX[%YCE
MN%>"CE.;8V>+?[R.+_+?_@H5^V5^T)-^T3)XP^$/CWXB>"_@YX&\27GPS\&Z
MAX<\1:YHO@WQWXV^&,VEZKX^O=2TJSU"UT[Q&+;7->@T)TU.WOM(U;P_8P@$
MK_:UI7]%OP1^/7A;XR?`+P=\>-/8P:'X@\''Q'JMK!BY?1]1TN*:'Q-I0(`W
MSZ%J]IJ6F.#@AK7DX%?C'^U'H/[*NG_L/)^RKIGQ&L=1^,?P'#:SI<UGX3\=
M7,FL?%G1[B\G^(UI!JT?AY=,G7QO=WGBG3K=[K63IMIJ-WI0O)=NE(J\Q_P1
M*_:(BCO?B#^R_P"*+M)++6(+KX@_#ZUO`DUL]W%%!9>.M!S-NWB[LO[+UFUT
MY(S;,+;Q%>LP6Y%>9P/QIF_"?CGC<AX@XLPN?8'Q2RG"XI+#9SA,XP?"'',8
MXKGX;3PN-<<''!XN.,R;"8=PP6+QF%AE<\5'F<I+U>.N!LDXQ^CS@.)>&^#<
M5P[F/A#G.)RJO4Q61XO),;QKP%46$]GQ74>+P2EC\;C,)+"9UC,2Z^887`5Z
M>9T\)*&"A&+]M_8O^*]K_P`%$_&_Q<U_XX_$WQ5I47AS68O^%??LY^!/B/XH
M^&&E:1X)NH8A;^*K^^\":UX4\4^.]0BO5-G?:E=ZO=VNEWP4FRM+35=)L[?Z
M&^)'[('Q;\`_%7X&^-?@-\9?C?J7PMTSXM^$I/B=\&/%/Q4\9>+-(M/"S:E`
ML^KZ+?>(M;N];NM!TTPQ+K?AK6+[5K.ZM9FU@#%E=6U_^77[5W_!++XZ?`;Q
MOJ'Q<_93N?$'BGP;:ZG>:_H^D^#]0O-.^*_P[4)<W+VFF0V-Q::AXDT_2TG%
MMI.H^'+JY\1BS<:?>Z-(+6[UF^]'_8O_`."N7C_1O%NB_!W]K)4U/2KW4XO#
M5O\`$Z:T_L?Q7X2U,S-9PP^.M,@M;>VU/3H+G[-:W^II9Z/JFD;;B]U!-8#,
M;7BX>XRP.1XO!^'OCUDF<\+\75<Y^MX/Q.6.Q?U'B/&1SB./PK>;QE!1RB3>
M$PKP36*X<PV"DL%B\!E%WA\/V\1\`8CB+"YAXD?1WS_(>*N"Z62O"8[PN>7Y
M:\VX8P<LCEE^,B^':E"I*>:QOB\93QW/A>)<3CXO&8+,<ZBE7Q/U+_P57\$?
MML>*-9^$TG[-,WQ)N?`UI::A#KVF_"C6[_1-=MO&D]\!8ZEXC&E:GI>H3:.-
M*,*Z3=;GTK2K^#46U%[7[98_:_U"^`5A\4=-^"GPPL/C1?0:A\4[/P/X?M?'
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MCS8F45^)^(.6Y]@?`SPAQ&-PO`-3A_&YIQ`\DSCAO`YI'C''>S5:6-7$^,QF
M!P*<<)B:F(PD8866,^M2PF%Q3DHX6#E]#4445_0Q_/84444`%%%%`!1110!2
M`S&N5QE<<E7^;:#CY1M.&P..,`YP.*\!^&GP(LOA'X^\=:UX*\03:9\.?B!(
M?$%]\*!IT;Z)X>^(-Q<LVM>+?"%[]H630['Q-!ND\1>&%M;K3+G6"-;L'TJ6
MYU&#4?H`[5^\?NX`R",D@8QM(.,<G@8'?!Q3G'RG:0&((R,%_4;><<'H">1G
MZ5YF)RO!8K$X/&5Z*EB<!B98K!8F_+B<*\5AGAL7%2BF_JN*@^3&85R>%Q24
M>>#>&P[CU83,L=@L-F&#P]>2P>:X6GA<=A%RRPN,6%Q*Q>$<H8E2C]:PF*CS
MX/%I1Q>$;J>SQ45BL7&I^1_[97_!-O7OB==>*_''[,GQ"O?A/XI\:O+>_$7X
M;IKNO>'_`(;_`!+OYR1?ZO<0^'V:VTCQ%J4`Q?\`VG2KW1_$5Z5OM1_L:_;5
MM9OOC7]C;_@DS\;O"OQN\$_$KX[/X<\,>$_AKXGTOQ;9Z+I'B&'7]<\4Z[X<
MO8-4\.Q0_P!D@Z;IVCIK%O9W=]<W=T;Z[L[8V!L,W?VRS_I#HKTSE/SK_P""
MC_Q2\%^$?V7/B_X(UG7;?_A,_'G@+4=&\*>$M-$FH>)]8N]5D73X+Z/1[)+F
M[AT2"Y2Y-[JD\$%I:M:RL+DW*"*OR(_X(X:]8_"+Q7^T+XW^)1O?!WA73?AY
MX-BO=9U?3=0MK6&2]\9II=F/FMO.N)+F]O;2WC$`*F2:,-@$,/Z?)(UE\M3M
M*#YMQW'Y>`K;N5R6SG=G&,*>*011E75E4*1\VW"HX[>9EBK<$_>`'7C&:_$.
M)_"C'\0^*'#/B4N)\-@JO"6"Q.#RC)WD/UM2EB<+FE\3C<6\]PSQ+6+QL9)8
M?"X7_9<*\(G*4I8J'[7PMXPX/AGPDXM\*EPMB<=1XSS;!X[.,[?$2PF+BL'B
M<I<<)@L$N'\5##Q^J95*/-B\7BO]LQ?USEY8+"3_``*_X*;?M5^#?C_\)K']
MGC]GW0_&7QD\7>)?%NDZ[K5YX5\"^+[ZQT/2_#WF7,$-C<3Z+:SZOJVHZA-:
MV@70;>^LK"R_M+[;J%K>FTL[OUS_`();_L.^+?A%\,]:\4_'C0#I7B'Q9XX\
M*>-_#?@34Q'<7OAM?"&C^)=-T'6=;A"D6/B&[E\4W>HKIH(NM'&G:.UZ;745
MN["T_9>*%$)$:1`DACM&T;/8#:P.,X)3:>*L,Q#$`@\8P<C!"G:,9Y.<=`,#
MJ3U!E_@_3Q'B5_Q%+BO/%GV>8;`_V3DV5X3*HY3D^48)X3%8-\V'KYGFF+QF
M+<<9C)*>*Q7*WBV_JMXX9X58SQGJX?PH?A#PIP_'(>'\=G']M9WFN-S:>=<1
MYSCEB\-C(1^N8?*\GP>!P:EA,(G3PF#<OJV'Y/K2C4Q:Q69J5U8Z?8W>HZI<
MVUG86%M/?7]Y=SK;V5A9VD+2SWEU/-LA@M[6W1KBZN+C"6\6XE]I)K^-7XN7
M,/[.?[=WB+XE_LW_`&OQ/X,\'?%"R\:^$M0\/:==7.@7=AK4-EK7BCP?97VG
MVIL[CP_;C5=;\$K<Z:MW:KH\0$ERCAD7^S[(Q@XVXXYR.IR#DGY<`G!Z?3-5
M?*CD<[%B,97=M(.T@GJH4&+''7;NSGC/-='B]X4R\4,-PY##YXN&L?PUF_\`
M;&!SC"Y2LTS7"XF,=(X24\SPD<)A_K,,-BY*2Q-\3A<(^6T7?#P:\7H^$N.X
MDKU^'%Q5E_%613X;SC(\7G$LHRK&X*I.\I8SV>58V>*Q$<++&8/"N+PG)A\;
MBVI7<4OC`?MT_`>WUC3-'\7ZOK/@5M>\+^'?''A2_P#$/A[Q&^B>*O!_BK2U
MU&QU*QU;3--O],L+ZRN5O=&U70/$-SI>K6NIZ;?6]G:7MD(;VZ_*7]L'X*6'
M_!0K]I+X92?LS^`=?M]#T_3KG3OC3^T#J?@S6/"7@2_L1>::NE_8;W7[#2I/
M%NO>&--MM3M8H]/L[JXU3^T]'L_M@T/2FN['^B>2"%C$V$5QQDD+O!&.H8,Q
MZG!)]QS4\<:+$ZQ@*#G."BL6`.[+=`#G`SSCKBNCB_PXQ_'^62X<XNSW*L;P
MV\TP>.Q6%P?#RPF;XF."Q,<7'!QS7$YWBL/@XR?-A<5B\%EF%QRP3>%6(A*6
M*Q.)XN!_$W!>&V>+BK@SA_-,#Q-3R?'93A<9FO$CS3)\-+'X*>"Q6->38;(,
MKQ.+E&FX8O"X+'9MBLOCF\/KSPLXQP6$PG\R/_!9_P`2^'/'7C[X,>$/A[=2
M^+K_`.&/A[QSHGBJ+0[:[UF/0+ZXU+PW;6VDZIJ=M!=P?VS;G0K^"^TU[E;R
MSO(1]M%I=!2?VJ_8.\=^#_&?[*_P1TGPUK-O?:OX'^$?PX\(^+]'=F@U?P[X
MDT7PII^D7^GZOITX%]9*U[I5XMC-<0+;ZG:PF\LGN;1E<_830H[$LH;C`8@L
M>!T+,Q&.V`!SZ5)$$5-J[0"6!"'@8!R.&..#D\C\:CACPPQO#OB5Q=XAU.(,
M)CH\6X3"8/%90L@6%>#PV58?"X;!+"XU9MB6[+"WQ?-A+8JZ4?JLHI&_%GBK
MA>*/"_@/PW_U<Q6!EP%BLRQ>#SM\0+%RQ^)SO$8G%9@\7@?[`PB@I8K$)X/D
MQTWA%%QG];YI25RBBBOV(_(@HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH
M`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`
:HHHH`****`"BBB@`HHHH`****`"BBB@#_]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>image_04.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_04.jpg
M_]C_X``02D9)1@`!`0```0`!``#_VP!#``$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0'_
MVP!#`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0'_P``1"``V`,$#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#^_'9R&"G&
M,#//;KZ^I!I1WS]T*0>G3D]^.O3UQ3MVX#L"N<\^O3\OY_GY)\6_BQHOPBT3
MPUK&M:?J6I0>*?B+\/\`X;6B:<+;S(-5^(OBW2_"&F7]S]KNK4'3K"^U:&YO
MC;F2\%G%(;.TN'VJ.7%8JA@\/5Q.+K*A0H<OUC$-6Y=HKH^LDM-F^YIA\-6Q
M>(IX7#4_;8FJI4L/AU;51A.<GZ*%*<FNT6CU^BBN>C\3^''UV;PQ'X@T63Q)
M;P_:9?#R:I9G7(;8P0S^?-I1N/[0\@PW$$_VC[.5VRJV<,-W49G0T5AKKVA-
MJ]QX?36]*;7K6R&HW.BKJ5D=7M=-S#"-1GTP7!NH;`//"INGM5M=]Q!EMS`'
MF/\`A;OPG_Z*?\//_"U\-_\`RSH`]#HKF=-\6>%];O3I^C>)M`U34EL;359+
M#3=9TZ^O%TJ]AM[BQU+[/;7,EP-.O(;VQGM+S9]ENH[FW*/BY!:S9>(]`U/4
M-2TG3=<T:_U71Y%CU?3;'4K.[U#2I3QMU.QM[AKFQ.<`+<JA;C`]0#=HKG['
MQ)X>U1M472O$&C:D^AS2VFMI8ZK97AT:[@,HGAU7[/<.=/EA-O-NM[K[*RB&
M?*_*=N7X:^(/@'QK/?6O@_QOX0\5W&F-LU*#PQXET?7KBPD/[G%]#IMW=/;$
M$X_TD#G&>!0!VE%5+FX@M()KFZFB@@MX99[BXFD$,,,,`,LLLLYP(885#$LS
M8"YW<`FN2TWXD?#W6KR.PT;QYX-U;4)VVPV&F^*-"O[V4]"(+>VU!KACUX"D
M@]!TR`=Q17,Z]XM\*^%1;'Q/XF\/^'%O?-^QOKVL:;HZW9M_)$_V=K^YM?M!
MMC-!O^SY*>?!G[P)S=,^(O@'699K?1_'?@S5KFVMKF_NH-.\3Z+J,\.GV1Q=
M7DT-K?L8;:U!S=W+!;:V(.\@'(`.XHK'T;6=)\06$.JZ'JFFZSI=PTGV;4M*
MOK34-/G\F5H9O(O+&:>VF^SSQ2V[%3\LD+H3E6)PM7^(?@/P]?-IGB#QOX0T
M/4D2*1K#6?$FCZ7?)%.,P2FSOKFVN`+C^'Y<'C:30!VM%<YH7BSPOXH2XE\,
M>)-!\1QVLD<=W+H6L:=J\5M+)DQ0W#Z?<W2P,P^8!B"0"PR`32:=XJ\,ZQJ>
MHZ+I7B+0M5U?27E35-*T[5].O-3TUX)OL\ZZA86]R]S8&"Y!MF%RB,MP=K`,
M.0#I**YGQ-XQ\)^"M/\`[6\8^*/#GA/2S((4U+Q-K>FZ!I[2X^6+[9JUU:VY
MF.,@;\D8`'>I8/$OAVYT3_A*+?Q!HESX:^S27P\0PZI9R:$+&$GS[TZJMP=/
M^SP>3(6NOM/EH%8EN#D`Z&BO//\`A;OPG_Z*?\//_"U\-_\`RSKT.@"NVW)8
M`$X!&/\`9(D`QUY(##K@<?1RS;BH"L-W<X`Z<X&2<`\9(P>"I93NI`5)^4]D
MQ[G`V>V><<^_M2DXP!@-M)'/!QGC'3Z<]_RIII126VFK:?K;\7MKON0I+5M.
M3<(SO'6\/9MJ/I%MRI]7%VO:Y-1114EA7Q=^W%_R('PB_P"SJ?V7_P#U=?@V
MOM&OB[]N+_D0/A%_V=3^R_\`^KK\&U\KQK_R2F?_`/8LK_\`I=,]_A/_`)*3
M*O\`L*E_Z@Y@?:-?S8_M+:]XH^%?_!3/XN?M'^'S<7&E?`-_@/X@\?Z;9QR2
M7%Y\.?&/A#P=X`\5?9QROG_9_$<%L!C`^W"^.1:$5_2=7X\:%X!T3XI_\%%O
MV_/AOXEC,F@^.?V=/A]X5U78@:6&UUOP?X!L3=V^0`U_:B8W5E<\?8[J"W92
M2`:^J/`-OPE?V>J?\%6OC%J>GW,%YIVH?L/6%_87ENP>WNK"]\5_#.XMKN"?
M&)[>Y@F%PI&0<`Y.03^>?["WPN_X)K>*_@)I^L?M0ZI\.K;XJR>)O$<-W!XD
M^,'C#P5JG]A6\T/]B9T71_&WA_3?LYM_."W*V/\`I1#9+;@H[_\`X)MZEXY_
MX;3^)_@CXCP>7XP^"_[)_BSX)ZE/F8F]A^'/Q.\`:'I4P^T$8M[71X+#2[(]
M+NRL+:^Z7>:D_P"">7C;_@GSH7[..E6'[1MG^SO<?$M/%GBF6Y?XD^`?#?B3
MQ/\`V+<7</\`90FU35_#FK77V$P>=]BMFNR`H(4`L<@'T]H_AWP9\$O^"F'[
M.'_"M([>R^&'QG_9,E\`>$Y+6^O-3T^ZT[P/IM[J^B0VVK7]S=7-_;#P]X/\
M#K8W=U>7MY=F>WY;[3FOG7]@?QY>:7^VY\6_BIXBOTB\%_M,^$_CY\0-"N=X
M\H_\(/\`&&^G_<9&;B#2O#^E:XRXP?LDPR<6F#[;_P`%+?$VB>#_``%^QM^U
M7\('TR[\,_#;QS+I'A*Y\,11:?H[^#?'/A!I[&#2[>"WMK>WL%TWP<MGHUL;
M>TLK3S_L.$%V`?D;]H+0M5_9T_8Z_P""?GQ4T.SDM]3M_A)\:/!M])#^XE2;
M]IOX8ZOK=E+.`#B?2KCQ'K>J"VR<WD)'&!0!Q]Q9>-X/^";.J?%KR=?7PQ\>
M?VQ=4\;_`!LN?#;S)JMQ\+F-_H<^FSS]M%/CG2)^+D\ZS>Z=8G_0;J\K]'OA
MM^S3^RI\3?BE\`_CW^PS\2_`'@!?A=J,M_\`$3PYX.GU+5-<\9^$[^;2H#X;
M\5Z'J'B*UUKPM?W&G?VWI=[=Z_I)O;W^VX#?K=BSL\W]0^*>N?L.?L.?LFR2
M_#O3/%G@:_L?`7AKXT_VJE[<)X2TWXBZ<?$7B34O[/M;:[&H*=7U/6M,%M=6
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MO#<GQ9T/X=?&GQM8?$;3[/\`L_QG!K/@#XA?$"XT.].NV`L]1N#I=AH-C:"T
MN";0V=F+(J%^8`'(_M)VLNO_``L_X)*V?[4\LR:7JFIZG:?%.;Q?J6H:-<_\
M(3/J?PMA\_Q3KD%S9:WIUR_@@6-SK6JM>V>K6EXMS?7]Z+_<3]M^!_A-_P`$
MY_#6@_&O7?V4KWP!J'Q-T_X"?%07J^%/BUXP\=:A;>%+C038ZM--HNL>-M?T
MW^SUU"?2K9KLV9^RW4UL%NE-V2WQ!\:/'FD^,?A?_P`$A/'/QTU*PU_P[<>)
MM='Q+U;QM#%XATO5?#NA^)/AII.N3>*H-0MKHZQ;W6CZ5,=:&I6UV+L_:C?B
MZ9BS?HM9?$3]@'4?"/Q?T?\`9L_X9_L/B1K'P6^*MF4^&/@?PWX6\27V@V_A
M6^U35;.:^T;PYI%Q/IPN-*LM3O;6YNOLC7-C:WC@M;6I`!N_\$G?^3$_@[_V
M$OB9_P"K.\8U\(?'KPI^S+XO_P""HGQ,TK]K&[\.6GPTB^`_A:\TV?Q7XRUC
MP/8'QC;Q>#H-+$&JZ#KGAZZN+@Z?/KBC3&O&M;P?:6:S9K3+>M_\$X?VP/V9
MOA1^R!\,?`GQ&^,O@_PCXOT>^\>/J>@ZK=7::C9QZK\0_%6K6!G$%H>;FPO8
M+OV\_.*\U\<>-/V8S_P4^\<^+?V@)OAEK/PD\0_LU^#]0\,W_P`2/#^F^*O#
M%_JNJV?@&_\`#MW86>LZ=JML-0NM!_M6YL;G[(+M;.>Y`VB[&(^Q\OU`_0WX
M`Z=^Q?\``;X1_%_XB?LO7/A:;X?>'[+5/$WQ#OO"OC[Q%XYL3?>#O#EWK;03
MWWB#Q)XA.G7]MHTQ86ELUIQ<PAU)"A?RA_8GMO$'P=_:*_92^.WBN[N5E_;K
M\-_'/3?&;S?\>X\4S^/+[Q)H<T/?_B?3P^!C9#KB_N?^GROH/]LKX[_LPV_[
M'/C_`.'?['LOPK6_^*?C[P)\-]1T3X1^'-)\,0/J'BJ:;59IK^QT?1])M+BY
MU[P[X'O_``_]JNE8FSGMK3<,V8/BG[6'P!_:]_9^^!GP=^(WC3XM_#WQWX+_
M`&3_`!=\,-0\$Z!X3\#0^'-6\.PZ5>Z%X<T2>77?[.M;F_MAJ,6AVEV+TW1O
M;R:WOKQ3=J#5@>D?':_^#-Q_P4X\6:-^V]'#)\'Y/A-X<L_@!)XWFU.V^'EE
M?7UGX5GUN\N)K&YM;:$W7B"#Q]:OJ>K$:3:7D$'V_#6FCW5GZQ?_`+,^C_L]
M_LF_MZZO\.OB7I7C/X&?%SP%XL\8_"WPGH,LVJ:%X'M8=&\207]OI?B,:YJ]
MOK]OJ=O/I6EF[M@!]E\.VHO6O3E:[7Q'^U9\`_BM\=/&/[/W[5'@OX0Z1\(Y
M_A[X3^)?P4\??%273;?2/&NC^,-!T35#>6.M^)UM-&T#43]NOK6QNM*U:TN_
MMFA:C8I>-?6@!^%/A98>']$\#?\`!5WP]\"-9U/5_P!E72_AMJB^!IWU#4=5
M\,0^+9_#6JS:O#X;O]1N+LZB+2`WMI_:MK=W=[K'ANQ\(WVH7MYG1[R@#I_V
M6O@K_P`$I_%GP,^$=S\7]1^&;_&+7-`L4\66.I?&_P`>>']9F\27%Y/;^3-H
M=AX_TJUTZYN?W!^RVUE:#H,8!K^B*OPL_9$^)'_!-'P_^SQ\&8_BE;_LR0_%
M?2_"]B_BB\\3_#KPIJ'B^#7[>[GF\S5-<N/"=UJ-QJ-N3;E;IKIKH8M^02*_
M<FVN(+RW@N[:19K>YACN+>5.8Y8IE$T,@[X(((Z'GD`\"8?"OG^8%JBBBJ`*
M***`(R"0#C!';\N@]O0]NM>+_&GX1VOQBT'PIH]UK$VB)X7^*'PR^)23Q6@O
MA?3_``Z\9Z/XOBT@@W-KY,&J2Z2-/>[.\V?G->?9+HJ$;V8DD8!Y'(///?GG
MCCGOZ<$<A.2=V"NT$_7`Y`QCTY^M<6,PF&S#"U<%C*,:^$Q"^KXG#-:-7C)*
M^]DU![K1&F%Q>(P.(ABL)4]EBL,I5L/B%NE.%2G+I97A5J1>FBD^NTU<S:^$
M_"]EXAU3Q79^'/#]GXIUJWM;+6?$UMHVG6_B#5K2R\J&QL]4UN&W&HZA;6BP
MP"SM[B[86H@MU55P,=-17:9G&V/@7P1IOB+5/%^G^#/"NG^+==MI+36O%%GX
M>TBV\0ZQ;3-:R3V>JZU!:_VGJ%M<&PL2]M=7-Q'_`*%:Y4_9K;;QO_#.O[/_
M`/T0OX-_^&P\%?\`REKV2B@#BM1^'O@#6/#=EX,U;P/X/U/P?IOV1=.\+:CX
M8T>]\-Z>+`F.Q6RT2XM'TRV^R`[;/[/:I]DS\FW(R:Y\/_`OBG1=/\->)_!/
MA+Q'X<TA[9]*\/:]X;T?5]"TR6PM)]/L9=/TK4;2ZL+`VMA<36=FUK;(;6SF
MFM$PK%*[6B@#$U'0M$UC1[GP_K&BZ7JV@7MF+&\T34M-LK[1[JRQM^QW.EW-
ML]K<6V`,VT]L;?``"C&*X;P3\$?@Q\,]0N-6^''PA^%_P_U.\@^S7>H^"?`'
MA7PIJ%S;#)\F:]T#2[*XG@'\-NSE=V#@=:]4HH`H7EG;7UK<V5]:P7EE>02V
MMY9W4$4]M>V\\9AGM[BWF+03P74+&W>"X7:ZE@P*YK$T_P`'>$M'\-GP7I/A
M7P[IG@][34+%O"6G:+IEEX:>QU::>;5K-M"@M4TS[+J4U_>O?6GV4VMX;RY-
MX&-RV>JHH`\PO?@W\(M2T;1O#^H?"GX<:AX?\/-?R>'M#O/`WA>XT?0GU647
M&J_V3ID^EFTTUM4N2;B^%G;VQO;D%KPLQ!J'1_@K\&_#UU+>^'OA-\--"O)K
M*[TV6]T;P%X5TNZFL;^%[*^LII['2K:=K'4;:6>VO;7YK:[M92K#:Q!]5HH`
M\;_X9U_9_P#^B%_!O_PV'@K_`.4M7-5^"7P8UZX@NM=^$GPPUN\M["PTZ"[U
M7P#X5U"Y@TW2K>*RTS3H9KW3)[B"PTVWAAMK*T4_9+.UB6U1%517K%%`'DUE
M\#?@IIS02:=\'/A9I\EK?6NJVLEG\//"EK);:I8G_0=2@\C1E,&H6@YM+Q2+
MNU'W&'(KO-=\/Z'XIT>[T'Q-HNE>(M#OQ$E_H^O:?9ZMI%_'#-%<0K>V&H6]
MU:W`@G@@N56YMV"W4*.`"H8;M%`'EGBCX*?!WQOIFAZ+XU^$WPU\7Z-X8MH[
M'PUH_BCP+X5\0:9X=L88(+:WL]#T_5]+N[;2+6WMH(+5;735MK86T04+@*B[
MFF?#SP!HOA-_`FC^"/"&D>")+:6QF\&Z7X9T:P\)RV5P3%<6<OAZWLDT5K:X
M7*W-O]C*NI(D4]^WHH`\;_X9U_9__P"B%_!O_P`-AX*_^4M>NQQ101I##'''
M'&H2*-$"(D8&!'%C`'`'3CV':>B@`HHHH`****`"BBB@`HHHH`****`"BBB@
G`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@#__9
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
